SEC 13F Intelligence

Managers / Q1 2023 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$520M
Q1 2023
Positions
118
Filings on Record
30
2019–present window
Filed
May 12, 2023
original filing

Summary

Sectoral Asset Management Inc reported $520M in U.S.-listed holdings across 118 positions for Q1 2023.

Its largest position, EVH, represents 3.1% of the portfolio.

Compared with Q4 2022, the fund opened 9 new positions and exited 11.

Portfolio Metrics

Turnover
+14.2%
vs prior filed quarter
Top-10 Concentration
+23.8%
share of reported value
Largest Position
+3.1%
Evolent Health
New / Exited
9 / 11
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 85.8%Other: 12.3%ADR: 1.2%ETP: 0.6%
  • Common Stock · 85.8% · $447M
  • Other · 12.3% · $64M
  • ADR · 1.2% · $6M
  • ETP · 0.6% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MLYSMINERALYS THERAPEUTINEW+613.2K613.2K+$10M$10M
TSVT*2SEVENTY BIO INCNEW+476.0K476.0K+$5M$5M
VERAVERA THERAPEUTICSNEW+600.3K600.3K+$5M$5M
RETAEURREATA PHARMACEUTICNEW+25.0K25.0K+$2M$2M
MERSANA THERAPEUTINEW+343.1K343.1K+$1M$1M
ANNXANNEXON INCNEW+326.8K326.8K+$1M$1M
PMVPPMV PHARMACEUTICALSNEW+250.5K250.5K+$1M$1M
MDGLMADRIGAL PHARMACEUTINEW+500500+$121,130$121,130

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1EVHEVOLENT HEALTH INChistory →CL A3.06%$16M491.1K
2R1 RCM INCCOM2.74%$14M949.2K
3SWAVUSDSHOCKWAVE MEDICALhistory →COM2.61%$14M62.5K
4UNHUNITEDHEALTH GRP INChistory →COM2.37%$12M26.1K
5BMRNBIOMARIN PHARMAC INChistory →COM2.33%$12M124.4K
6PROMETHEUS BIOSCIENCCOM2.23%$12M108.1K
7APLSUSDAPELLIS PHARMACEUTIChistory →COM2.19%$11M172.5K
8PTCTPTC THERAPEUTICS Ihistory →COM2.11%$11M226.6K
9ICON PLCSHS2.07%$11M50.5K
10HQYHEALTHEQUITY INChistory →COM2.07%$11M183.4K
11LNTHLANTHEUS HLDGS INChistory →COM1.87%$10M117.7K
12JNJJOHNSON & JOHNSONhistory →COM1.85%$10M62.1K
13MLYSMINERALYS THERAPEUTIhistory →COM1.85%$10M613.2K
14OPCHOPTION CARE HEALTHhistory →COM1.82%$9M298.5K
15INARI MED INCCOM1.82%$9M153.0K
16TMCITREACE MED CONCEPThistory →COM1.77%$9M366.4K
17IM8NINSMED INChistory →COM1.69%$9M516.1K
18LLYLILLY ELI & COhistory →COM1.57%$8M23.8K
19AGILITI INCCOM1.57%$8M510.2K
20TVTXTRAVERE THERAPEUTICShistory →COM1.55%$8M358.6K
21RDNTRADNET INChistory →COM1.51%$8M312.9K
22PRVAPRIVIA HEALTH GROUPhistory →COM1.49%$8M280.3K
23IRTCIRHYTHM TECHNOLOGIEShistory →COM1.41%$7M59.1K
24AMLXAMYLYX PHARMACEUTIChistory →COM1.37%$7M242.4K
25ATRCATRICURE INChistory →COM1.27%$7M159.5K
26ALKERMES PLCSHS1.25%$7M231.1K
27INSPINSPIRE MED SYS INChistory →COM1.24%$6M27.5K
28PFEPFIZER INChistory →COM1.23%$6M157.4K
29ABBVABBVIE INChistory →COM1.20%$6M39.3K
30ITCIEURINTRA CELLULAR THERAhistory →COM1.19%$6M114.2K
31THCTENET HEALTHCAREhistory →COM1.16%$6M101.5K
32AXNX*AXONICS INChistory →COM1.15%$6M110.0K
33PROTHENA CORP PLCSHS1.14%$6M122.8K
34MRKMERCK & CO INChistory →COM1.12%$6M55.0K
35AM6AMICUS THERAPEUTICShistory →COM1.11%$6M520.0K
36DNLIDENALI THERAPEUTICShistory →COM1.08%$6M244.8K
37ARVNARVINAS INChistory →COM1.08%$6M205.1K
38BLUBELLUS HEALTH INChistory →COM NEW1.06%$6M767.8K
392655787DBLUEPRINT MEDICINEShistory →COM1.05%$5M121.9K
40GRTXGALERA THERAPEUTIChistory →COM1.03%$5M2.10M
41RCUSARCUS BIOSCIENCEShistory →COM1.03%$5M293.6K
42ALNYALNYLAM PHARMACUETCLhistory →COM1.02%$5M26.6K
43AMGNAMGEN INChistory →COM1.02%$5M21.9K
44CTIC1USDCTI BIOPHARMA CORPhistory →COM1.01%$5M1.25M
45SPRYARS PHARMACEUTICALSCOM0.99%$5M793.6K
46BSXBOSTON SCIENTIFICCOM0.98%$5M102.0K
47KARUNA THERAPEUTICSCOM0.94%$5M26.9K
48TSVT*2SEVENTY BIO INCCOM0.93%$5M476.0K
49MRTXEURMIRATI THERAPEUTICSCOM0.92%$5M128.4K
50VERAVERA THERAPEUTICSCL A0.90%$5M600.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.